Table 2.

Cytotoxicity of 1,7-Diheteroarylhepta-1,4,6-trien-2-ones

Compd	Inhibitory Rate (%)
	PC-3a		DU145b		LNCaPc		HeLad
	10 μM	1 μM	10 μM	1 μM	10 μM	1 μM	10 μM	1 μM
Curcumin	55	2.5	59	7	66	29	50	14
6	83	35	66	21	55	41	93	18
7	85	32	84	34	62	23	98	43
8	91	23	84	25	95	38	98	34
9	87	33	91	35	92	47	92	44
10	86	36	88	43	94	44	95	39
11	85	11	86	34	76	31	98	32
12	92	28	93	25	70	12	99	13
13	92	48	86	46	79	69	97	62
14	86	47	88	52	81	67	95	62
15	86	60	93	77	79	29	94	83
16	89	32	88	32	75	33	95	31
17	92	56	87	65	89	74	95	85
18	95	70	82	55	88	58	97	87
19	87	35	75	0	70	38	94	66
20	86	25	46	8	57	21	96	20
21	86	28	65	2	80	28	94	11
22	88	25	79	25	70	13	97	17
23	88	24	80	13	92	37	96	12
24	91	25	86	42	63	38	95	52
25	86	24	87	24	61	2	97	20
26	20	17	37	11	7.2	0	24	21
27	91	35	75	12	57	50	94	40
28	84	33	81	60	50	20	95	22
29	84	19	81	36	66	31	94	26
30	88	80	77	57	77	52	89	95
31	89	67	79	42	48	5	97	76
32	82	86	75	73	72	54	95	96
33	87	75	89	64	76	10	95	68
34	93	58	97	21	60	15	97	53
35	89	83	75	56	64	45	94	89

^aHuman androgen-insensitive prostate cancer cell line

^bHuman androgen-insensitive prostate cancer cell line

^cHuman androgen-sensitive prostate cancer cell line

^dHuman aggressive cervical cancer cell line